A Novel Anti-CXCR4 Antibody for Relapsed/Refractory Multiple Myeloma

Clinical Pearls

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.

• This trial analyzed the anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide and low-dose dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.
• Patients achieved a nearly 56% overall response rate.
• Many patients on the trial were refractory to lenalidomide.

More on this study > >